Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Teva Pharmaceutical Industries / Equity Bottom-Up

<ul>
<li>Teva Pharmaceutical Industries has moved deeper into innovative neuroscience with its planned acquisition of Emalex Biosciences, a deal centered on ecopipam, an NDA-ready, first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome.</li>
<li>The transaction includes $700 million in upfront cash, up to $200 million in commercial milestones, and royalties tied to future sales, subject to approval.</li>
<li>Ecopipam has already produced positive Phase 3 data, carries FDA Orphan Drug and Fast Track designations, and is expected to be submitted for approval in the second half of 2026.</li>
</ul>


Teva Pharmaceutical Industries has moved deeper into innovative neuroscience with its planned acquisition of Emalex Biosciences, a deal centered on ecopipam, an NDA-ready, first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome.
The transaction includes $700 million in upfront cash, up to $200 million in commercial milestones, and royalties tied to future sales, subject to approval.
Ecopipam has already produced positive Phase 3 data, carries FDA Orphan Drug and Fast Track designations, and is expected to be submitted for approval in the second half of 2026.


Teva Pharma's $700 Million Emalex Buyout Signals The Pivot To Growth Is Real!